An impact of lipid profile and lipid lowering drugs on ≥70 year olds of an upper socioeconomic class: a retrospective cohort study

Table 3 List of malignancies diagnosed before or during active surveillance in the institute for medical screening

Malignancy category	1st malignancy diagnosed pre-IMS surveillance			1st malignancy diagnosed during IMS surveillance			Second and additional malignancies diagnosed during IMS surveillance
Malignancy category	Men	Women	Total	Men	Women	Total	Men	Women	Total^†b
Breast	0	22	22	1	39	40	1	4	5
Lung	2	1	3	15	3	18	1	1	2
Gastrointestinal^*	16	5	21	40	4	44	8	0	8
Genitourinary^‡	49	3	52	147	5	152	33	1	34
Hematologic^§	12	3	15	56	14	70	5	7	12
Gynecologic^ǁ	0	6	6	0	4	4	0	2	2
Melanoma	18	13	31	55	9	64	14	1	15
Other^¶	8	3	11	9	5	14	5	5	10

^*Gastrointestinal- colorectal, pancreas, biliary, stomach, esophagus and liver; ^‡Genitourinary- prostate, kidney, urothelial, bladder, testicular; ^§Hematologic- leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, multiple myeloma and myelodysplastic syndrome; ^ǁGynecologic- ovarian, uterine, cervical; ^¶Other- head and neck, brain, thyroid, sarcoma, skin cancer requiring systemic therapy other than melanoma, or primary unknown; †15 cases of second malignancy were diagnosed prior to the IMS surveillance: 2 breast, 2 gastrointestinal, 3 genitourinary, 2 hematologic, 1 gynecologic, 4 melanoma and 1 other (advanced squamous cell carcinoma)

ISSN: 1476-511X